|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Connell JB, Maggard MA and Ko CY: Colon
cancer survival rates with the new American Joint Committee on
cancer sixth edition staging. J Natl Cancer Inst. 96:1420–1425.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moriarity A, O'Sullivan J, Kennedy J,
Mehigan B and McCormick P: Current targeted therapies in the
treatment of advanced colorectal cancer: A review. Ther Adv Med
Oncol. 8:276–293. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de Mestier L, Manceau G, Neuzillet C,
Bachet JB, Spano JP, Kianmanesh R, Vaillant JC, Bouché O, Hannoun L
and Karoui M: Primary tumor resection in colorectal cancer with
unresectable synchronous metastases: A review. World J Gastrointest
Oncol. 6:156–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raymond E, Faivre S, Woynarowski JM and
Chaney SG: Oxaliplatin: Mechanism of action and antineoplastic
activity. Semin Oncol. 25:4–12. 1998.PubMed/NCBI
|
|
7
|
Benson AB, Venook AP, Al-Hawary MM,
Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Engstrom PF, et al: NCCN guidelines insights: Colon cancer, version
2.2018. J Natl Compr Canc Netw. 16:359–369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bahrami A, Amerizadeh F, Hassanian SM,
ShahidSales S, Khazaei M, Maftouh M, Ghayour-Mobarhan M, Ferns GA
and Avan A: Genetic variants as potential predictive biomarkers in
advanced colorectal cancer patients treated with oxaliplatin-based
chemotherapy. J Cell Physiol. 233:2193–2201. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hammond WA, Swaika A and Mody K:
Pharmacologic resistance in colorectal cancer: A review. Ther Adv
Med Oncol. 8:57–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yan D, Tu L, Yuan H, Fang J, Cheng L,
Zheng X and Wang X: WBSCR22 confers oxaliplatin resistance in human
colorectal cancer. Sci Rep. 7:154432017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mao L, Li Y, Zhao J, Li Q, Yang B, Wang Y,
Zhu Z, Sun H and Zhai Z: Transforming growth factor-β1 contributes
to oxaliplatin resistance in colorectal cancer via epithelial to
mesenchymal transition. Oncol Lett. 14:647–654. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gnoni A, Russo A, Silvestris N, Maiello E,
Vacca A, Marech I, Numico G, Paradiso A, Lorusso V and Azzariti A:
Pharmacokinetic and metabolism determinants of fluoropyrimidines
and oxaliplatin activity in treatment of colorectal patients. Curr
Drug Metab. 12:918–931. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Conti JA, Kemeny NE, Saltz LB, Huang Y,
Tong WP, Chou TC, Sun M, Pulliam S and Gonzalez C: Irinotecan is an
active agent in untreated patients with metastatic colorectal
cancer. J Clin Oncol. 14:709–715. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cecchin E, Corona G, Masier S, Biason P,
Cattarossi G, Frustaci S, Buonadonna A, Colussi A and Toffoli G:
Carboxylesterase isoform 2 mRNA expression in peripheral blood
mononuclear cells is a predictive marker of the irinotecan to SN38
activation step in colorectal cancer patients. Clin Cancer Res.
11:6901–6907. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chabot GG, Robert J, Lokiec F and Canal P:
Irinotecan pharmacokinetics. Bull Cancer. 11–20. 1998.(In French).
PubMed/NCBI
|
|
16
|
Hecht JR: Gastrointestinal toxicity of
irinotecan. Oncology (Williston Park). 12:72–78. 1998.PubMed/NCBI
|
|
17
|
Xu Y and Villalona-Calero M: Irinotecan:
Mechanisms of tumor resistance and novel strategies for modulating
its activity. Ann Oncol. 13:1841–1851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ransohoff JD, Wei Y and Khavari PA: The
functions and unique features of long intergenic non-coding RNA.
Nat Rev Mol Cell Biol. 19:143–157. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim T and Croce CM: Long noncoding RNAs:
Undeciphered cellular codes encrypting keys of colorectal cancer
pathogenesis. Cancer Lett. 417:89–95. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li H, Ma SQ, Huang J, Chen XP and Zhou HH:
Roles of long noncoding RNAs in colorectal cancer metastasis.
Oncotarget. 8:39859–39876. 2017.PubMed/NCBI
|
|
22
|
Han D, Wang M, Ma N, Xu Y, Jiang Y and Gao
X: Long noncoding RNAs: Novel players in colorectal cancer. Cancer
Lett. 361:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang
R, Jin Y, Zou C, Chen Y, Wang G, et al: Long non-coding RNA H19
confers 5-Fu resistance in colorectal cancer by promoting
SIRT1-mediated autophagy. Cell Death Dis. 9:11492018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li L, Shang J, Zhang Y, Liu S, Peng Y,
Zhou Z, Pan H, Wang X, Chen L and Zhao Q: MEG3 is a prognostic
factor for CRC and promotes chemosensitivity by enhancing
oxaliplatin-induced cell apoptosis. Oncol Rep. 38:1383–1392. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luo J, Qu J, Wu DK, Lu ZL, Sun YS and Qu
Q: Long non-coding RNAs: A rising biotarget in colorectal cancer.
Oncotarget. 8:22187–22202. 2017.PubMed/NCBI
|
|
26
|
Jensen NF, Stenvang J, Beck MK, Hanáková
B, Belling KC, Do KN, Viuff B, Nygård SB, Gupta R, Rasmussen MH, et
al: Establishment and characterization of models of chemotherapy
resistance in colorectal cancer: Towards a predictive signature of
chemoresistance. Mol Oncol. 9:1169–1185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yi Y, Zhao Y, Li C, Zhang L, Huang H, Li
Y, Liu L, Hou P, Cui T, Tan P, et al: RAID v2. 0: An updated
resource of RNA-associated interactions across organisms. Nucleic
Acids Res. 45:D115–D118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Szklarczyk D, Gable AL, Lyon D, Junge A,
Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork
P, et al: STRING v11: Protein-protein association networks with
increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic Acids Res. 47:D607–D613. 2018.
View Article : Google Scholar :
|
|
32
|
Scardoni G, Tosadori G, Faizaan M, Spoto
F, Fabbri F and Laudanna C: Biological network analysis with
CentiScaPe: Centralities and experimental dataset integration.
F1000Res. 3:e1392014. View Article : Google Scholar
|
|
33
|
Cui T, Zhang L, Huang Y, Yi Y, Tan P, Zhao
Y, Hu Y, Xu L, Li E and Wang D: MNDR v2.0: An updated resource of
ncRNA-disease associations in mammals. Nucleic Acids Res.
46:D371–D374. 2018.PubMed/NCBI
|
|
34
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Patel GK, Khan MA, Bhardwaj A, Srivastava
SK, Zubair H, Patton MC, Singh S, Khushman M and Singh AP: Exosomes
confer chemoresistance to pancreatic cancer cells by promoting ROS
detoxification and miR-155-mediated suppression of key
gemcitabine-metabolising enzyme, DCK. Br J Cancer. 116:609–619.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen WX, Liu XM, Lv MM, Chen L, Zhao JH,
Zhong SL, Ji MH, Hu Q, Luo Z, Wu JZ and Tang JH: Exosomes from
drug-resistant breast cancer cells transmit chemoresistance by a
horizontal transfer of microRNAs. PLoS One. 9:e952402014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ji R, Zhang B, Zhang X, Xue J, Yuan X, Yan
Y, Wang M, Zhu W, Qian H and Xu W: Exosomes derived from human
mesenchymal stem cells confer drug resistance in gastric cancer.
Cell Cycle. 14:2473–2483. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu Y, Yan C, Mu L, Huang K, Li X, Tao D,
Wu Y and Qin J: Fibroblast-derived exosomes contribute to
chemoresistance through priming cancer stem cells in colorectal
cancer. PLoS One. 10:e01256252015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brinton LT, Sloane HS, Kester M and Kelly
KA: Formation and role of exosomes in cancer. Cell Mol Life Sci.
72:659–671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ding C, Han F, Xiang H, Xia X, Wang Y, Dou
M, Zheng J, Li Y, Xue W, Ding X and Tian P: LncRNA CRNDE is a
biomarker for clinical progression and poor prognosis in clear cell
renal cell carcinoma. J Cell Biochem. 119:10406–10414. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang H, Ke J, Guo Q, Barnabo Nampoukime
KP, Yang P and Ma K: Long non-coding RNA CRNDE promotes the
proliferation, migration and invasion of hepatocellular carcinoma
cells through miR-217/MAPK1 axis. J Cell Mol Med. 22:5862–5876.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Y, Wang Y, Li J, Zhang Y, Yin H and
Han B: CRNDE, a long-noncoding RNA, promotes glioma cell growth and
invasion through mTOR signaling. Cancer Lett. 367:122–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu T, Zhang X, Gao S, Jing F, Yang Y, Du
L, Zheng G, Li P, Li C and Wang C: Exosomal long noncoding RNA
CRNDE-h as a novel serum-based biomarker for diagnosis and
prognosis of colorectal cancer. Oncotarget. 7:85551–85563. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ding J, Li J, Wang H, Tian Y, Xie M, He X,
Ji H, Ma Z, Hui B, Wang K and Ji G: Long noncoding RNA CRNDE
promotes colorectal cancer cell proliferation via epigenetically
silencing DUSP5/CDKN1A expression. Cell Death Dis. 8:e29972017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu
XY, Yu ZW, Jia YH, Bai XF, Li L, et al: The lncRNA CRNDE promotes
colorectal cancer cell proliferation and chemoresistance via
miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Mol
Cancer. 16:92017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gao H, Song X, Kang T, Yan B, Feng L, Gao
L, Ai L, Liu X, Yu J and Li H: Long noncoding RNA CRNDE functions
as a competing endogenous RNA to promote metastasis and oxaliplatin
resistance by sponging miR-136 in colorectal cancer. Onco Targets
Ther. 10:205–216. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Han J, Han B, Wu X, Hao J, Dong X, Shen Q
and Pang H: Knockdown of lncRNA H19 restores chemo-sensitivity in
paclitaxel-resistant triple-negative breast cancer through
triggering apoptosis and regulating Akt signaling pathway. Toxicol
Appl Pharmacol. 359:55–61. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li M, Chai HF, Peng F, Meng YT, Zhang LZ,
Zhang L, Zou H, Liang QL, Li MM, Mao KG, et al: Estrogen receptor β
upregulated by lncRNA-H19 to promote cancer stem-like properties in
papillary thyroid carcinoma. Cell Death Dis. 9:11202018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang Z, Lei W, Hu HB, Zhang H and Zhu Y:
H19 promotes non-small-cell lung cancer (NSCLC) development through
STAT3 signaling via sponging miR-17. J Cell Physiol. 233:6768–6776.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung
JJ and Kwok TT: Oncofetal H19-derived miR-675 regulates tumor
suppressor RB in human colorectal cancer. Carcinogenesis.
31:350–358. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Han D, Gao X, Wang M, Qiao Y, Xu Y, Yang
J, Dong N, He J, Sun Q, Lv G, et al: Long noncoding RNA H19
indicates a poor prognosis of colorectal cancer and promotes tumor
growth by recruiting and binding to eIF4A3. Oncotarget.
7:22159–22173. 2016.PubMed/NCBI
|
|
52
|
Yang W, Redpath RE, Zhang C and Ning N:
Long non-coding RNA H19 promotes the migration and invasion of
colon cancer cells via MAPK signaling pathway. Oncol Lett.
16:3365–3372. 2018.PubMed/NCBI
|
|
53
|
Ma H, Yuan L, Li W, Xu K and Yang L: The
LncRNA H19/miR-193a-3p axis modifies the radio-resistance and
chemotherapeutic tolerance of hepatocellular carcinoma cells by
targeting PSEN1. J Cell Biochem. 119:8325–8335. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Si X, Zang R, Zhang E, Liu Y, Shi X, Zhang
E, Shao L, Li A, Yang N, Han X, et al: LncRNA H19 confers
chemoresistance in ERα-positive breast cancer through epigenetic
silencing of the pro-apoptotic gene BIK. Oncotarget. 7:81452–81462.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wu KF, Liang WC, Feng L, Pang JX, Waye MM,
Zhang JF and Fu WM: H19 mediates methotrexate resistance in
colorectal cancer through activating Wnt/β-catenin pathway. Exp
Cell Res. 350:312–317. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang N, Meng X, Liu Y, Chen Y and Liang Q:
LPS promote Osteosarcoma invasion and migration through
TLR4/HOTAIR. Gene. 680:1–8. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kim HJ, Lee DW, YIm GW, Nam EJ, Kim S, Kim
SW and Kim YT: Long non-coding RNA HOTAIR is associated with human
cervical cancer progression. Int J Oncol. 46:521–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Xian HP, Zhuo ZL, Sun YJ, Liang B and Zhao
XT: Circulating long non-coding RNAs HULC and ZNFX1-AS1 are
potential biomarkers in patients with gastric cancer. Oncol Lett.
16:4689–4698. 2018.PubMed/NCBI
|
|
59
|
Lin K, Jiang H, Zhang LL, Jiang Y, Yang
YX, Qiu GD, She YQ, Zheng JT, Chen C, Fang L and Zhang SY:
Down-regulated LncRNA-HOTAIR suppressed colorectal cancer cell
proliferation, invasion, and migration by mediating p21. Dig Dis
Sci. 63:2320–2331. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lu X, Liu Z, Ning X, Huang L and Jiang B:
The long noncoding RNA HOTAIR promotes colorectal cancer
progression by sponging miR-197. Oncol Res. 26:473–481. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Luo ZF, Zhao D, Li XQ, Cui YX, Ma N, Lu
CX, Liu MY and Zhou Y: Clinical significance of HOTAIR expression
in colon cancer. World J Gastroenterol. 22:5254–5259. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li P, Zhang X, Wang L, Du L, Yang Y, Liu
T, Li C and Wang C: lncRNA HOTAIR contributes to 5FU resistance
through suppressing miR-218 and activating NF-κB/TS signaling in
colorectal cancer. Mol Ther Nucleic Acids. 8:356–369. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Xiao Z, Qu Z, Chen Z, Fang Z, Zhou K,
Huang Z, Guo X and Zhang Y: LncRNA HOTAIR is a prognostic biomarker
for the proliferation and chemoresistance of colorectal cancer via
MiR-203a-3p-mediated Wnt/ss-catenin signaling pathway. Cell Physiol
Biochem. 46:1275–1285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang HM, Lu JH, Chen WY and Gu AQ:
Upregulated lncRNA-UCA1 contributes to progression of lung cancer
and is closely related to clinical diagnosis as a predictive
biomarker in plasma. Int J Clin Exp Med. 8:11824–11830.
2015.PubMed/NCBI
|
|
65
|
Shalini S, Dorstyn L, Dawar S and Kumar S:
Old, new and emerging functions of caspases. Cell Death Differ.
22:526–539. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Li JY, Ma X and Zhang CB: Overexpression
of long non-coding RNA UCA1 predicts a poor prognosis in patients
with esophageal squamous cell carcinoma. Int J Clin Exp Pathol.
7:7938–7944. 2014.PubMed/NCBI
|
|
67
|
Han Y, Yang YN, Yuan HH, Zhang TT, Sui H,
Wei XL, Liu L, Huang P, Zhang WJ and Bai YX: UCA1, a long
non-coding RNA up-regulated in colorectal cancer influences cell
proliferation, apoptosis and cell cycle distribution. Pathology.
46:396–401. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu
Y, Feng Y, Liu H, Fei B, Mao Y, et al: LncRNA-UCA1 enhances cell
proliferation and 5-fluorouracil resistance in colorectal cancer by
inhibiting miR-204-5p. Sci Rep. 6:238922016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yang X, Liu W, Xu X, Zhu J, Wu Y, Zhao K,
He S, Li M, Wu Y, Zhang S, et al: Downregulation of long noncoding
RNA UCA1 enhances the radiosensitivity and inhibits migration via
suppression of epithelialmesenchymal transition in colorectal
cancer cells. Oncol Rep. 40:1554–1564. 2018.PubMed/NCBI
|
